Physician profile
Stephen D Smith
NPI 1497925051
$44,684.33
in general payments reported to CMS, 2019-2025
20 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.10 · 2020: $11K · 2021: $6,169 · 2022: $6,113 · 2023: $15K · 2024: $3,905 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $2,206 · Food and Beverage: $1,310 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,370.00 |
| Travel and Lodging | $2,205.97 |
| Food and Beverage | $1,309.63 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $272.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $9,997.30 | 2020-2025 | Calquence |
| Kite Pharma, INC. | $7,899.96 | 2020-2023 | Yescarta |
| Genentech USA, INC. | $7,299.10 | 2019-2024 | Columvi, Lunsumio, Venclexta |
| Genentech, INC. | $6,000.00 | 2023 | Polivy |
| Incyte Corporation | $5,227.50 | 2020-2021 | |
| Beigene USA, INC. | $2,136.82 | 2021-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $1,937.50 | 2020 | |
| Adc Therapeutics America, INC. | $1,800.86 | 2022-2025 | |
| Beone Medicines USA, INC. | $800.00 | 2025 | Brukinsa |
| Epizyme, INC. | $711.50 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $610.00 | 2024 | |
| Taiho Oncology, INC. | $131.64 | 2023-2024 | |
| Seagen INC. | $73.40 | 2022 | |
| Astrazeneca Uk Limited | $58.75 | 2023 | Calquence |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.